<DOC>
	<DOCNO>NCT01087788</DOCNO>
	<brief_summary>Phase 3 , multicenter , randomize , double-blind , parallel-group , placebo-controlled study evaluate efficacy safety Certolizumab Pegol ( CZP ) subject adult onset active progressive Psoriatic Arthritis ( PsA ) .</brief_summary>
	<brief_title>Certolizumab Pegol Subjects With Adult Onset Active Progressive Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Diagnosis adultonset Psoriatic Arthritis ( PsA ) least 6 month ' duration define Classification Criteria Psoriatic Arthritis ( CASPAR criterion ) Active Psoriatic Skin Lesions document history Psoriasis Active Arthritis ≥ 3 tender joint Screening Baseline , ≥ 3 swollen joint Screening Baseline fulfil least 1 follow 2 criterion Screening Period : 1 . Erythrocyte Sedimentation Rate ( ESR ) ( Westergren ) ≥ 28 mm/hour 2 . Creactive protein ( CRP ) &gt; Upper Limit Normal ( ULN ) Failure 1 treatment DiseaseModifying AntiRheumatic Drugs ( DMARDs ) Diagnosis inflammatory Arthritis know diagnosis Fibromyalgia Exposure 1 Tumor Necrosis Factor α ( TNFα ) antagonist 2 previous biological response modifier PsA Psoriasis Any nonbiological systemic treatment Psoriasis ; phototherapy ; topical agent History chronic recurrent infection High risk infection Live vaccination within 8 week prior Baseline Concurrent malignancy history malignancy Class III IV congestive Heart Failure New York Heart Association ( NYHA ) Demyelinating disease central nervous system Clinically significant laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>